Ellele Sampling Device
We developed a proprietary, minimally invasive vaginal sampling device that collects a richer and more representative vaginal sample.
We developed a proprietary, minimally invasive vaginal sampling device that collects a richer and more representative vaginal sample.
We are leveraging our in-house hologenomic pipeline to identify novel biomarkers for the diagnosis of endometrial and ovarian cancers.
We are building a biobank of biological samples and omics databank to address and bridge a long-standing data gap in Women’s Health.
Ellele Health was founded in 2024 to advance the next generation of diagnostics across gynaecological conditions through better sampling methods. The company builds on the foundation of its parent company, TOGL, whose proprietary mucosal sampling technology and hologenomic pipeline were used to develop a superior diagnostic for colorectal cancer [1].
Recognising limited innovation in vaginal sampling methods, Ellele Health extends this validated approach to address significant unmet need in gynaecological care. We created the proprietary Ellele Sampling Device to address analytical requirements of the next-generation multiomics-based diagnostics while keeping patients’ comfort and dignity at the centre of the design. We have since used the Ellele Sampling Device to support the discovery of novel biomarkers across gynaecological conditions, starting with ovarian and endometrial cancers.
We envision a world where every woman has access to early and accurate diagnosis for all gynaecological conditions, across life stages and without discomfort or shame.
Our mission is to use the Ellele Sampling Device to:
The name Ellele unites allele – the fundamental unit of genetic variation – with elle, the French word for “her”.
It reflects our belief that Women’s Health warrants the same depth of scientific research and innovation that has driven advances across other fields - with empathy and respect.